Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Frontiers in Pharmacology|November 2, 2017
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy VolunteersDavid Monteith, Emily C Collins, Corinne Vandermeulen, et al.
JAMA Neurology|October 17, 2022
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical TrialMichael J Pontecorvo, Ming Lu, Samantha C Burnham, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Understanding recent advances in non-amyloid/non-tau (NANT) biomarkers and therapeutic targets in Alzheimer's diseaseLinda J Van Eldik, Eric R Siemers, Emily C Collins, et al.
Plos One|December 5, 2012
Glucose metabolic trapping in mouse arteries: nonradioactive assay of atherosclerotic plaque inflammation applicable to drug discoveryRichard G Conway, Eyassu Chernet, David C De Rosa, et al.
JAMA Neurology|October 13, 2025
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical TrialMing Lu, Min Jung Kim, Emily C Collins, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|July 2, 2025
Clinical validation of the Lilly SP-X P-tau217 assay: Performance in underrepresented cohortsMichael E Hodsdon, Adam Abel, Antonio Chambers, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumChris Conklin, Stefan Radonjic, David Scott, et al.
The Journal of Applied Laboratory Medicine|January 21, 2025
Analytical Validation and Performance of a Blood-Based P-tau217 Diagnostic Test for Alzheimer DiseaseAdam Abel, Antonio Chambers, Jeff Fill, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|December 18, 2014
Increased cerebral vascular reactivity in the tau expressing rTg4510 mouse: evidence against the role of tau pathology to impair vascular health in Alzheimer's diseaseJack A Wells, Holly E Holmes, James M O'Callaghan, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 21, 2023
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's diseaseSergey Shcherbinin, Amanda Morris, Ixavier A Higgins, et al.
Pageof 4